Combination of NMDA-enhancing and Anti-inflammatory Treatments for Ultra-resistant Schizophrenia
Status:
Not yet recruiting
Trial end date:
2027-03-01
Target enrollment:
Participant gender:
Summary
Previous study found that some NMDA-enhancing agent was able to augment efficacy of clozapine
for clinical symptoms but not cognitive function in the treatment of ultra-resistant
schizophrenia. In addition, several drugs with anti-inflammatory properties have been tested
in clinical trials for the treatment of schizophrenia. Whether a drug with anti-inflammatory
property can strengthen the efficacy of an NMDA-enhancer (NMDAE) in the treatment of
ultra-resistant schizophrenia remains unknown.